SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet is trending due to a community divided between short-term concerns over token unlocks and strong belief in its advanced ZK-STARKs technology, quantum resistance, and growing ecosystem metrics like TVL, active users, and BTCFi integrations. Many argue the platform is currently undervalued given its consistent development and strategic positioning as essential infrastructure for Ethereum scaling.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE crypto is trending with high community engagement, fueled by speculation of a renewed 'meme season' and aspirations for significant price appreciation. Chatter reflects a mix of strong bullish predictions for a major rally and caution regarding volatility, frequently discussed in conjunction with broader crypto market trends.

Moo Deng

Recent volatile price swings and high trading volume are driving extensive community discussion around MOODENG CRYPTO. Investors are debating its potential for massive future pumps as a low market cap Solana meme coin, while also grappling with concerns over sharp drops.

Eikon Therapeutics is a biopharmaceutical company. It engages in the development of medicines for unmet medical needs. The company was founded in 2019 and is headquartered in Millbrae, CA.

Eikon Therapeutics Inc.

Eikon Therapeutics is trending as its EIK1001 TLR7/8 agonist gains community attention for potential integration into NWBO's advanced combinatorial DCVax booster platform for personalized immunotherapies, fueled by discussions around recent insider buying.

USDX (Website: usdx.money | Twitter: @StablesLabs) is a synthetic USD stablecoin designed to provide stability without relying on traditional banking infrastructure. Backed by delta-neutral positions across multiple exchanges, USDX seamlessly bridges the gap between DeFi, CeFi, and TradFi. It enables DeFi users to access traditional delta-neutral strategies executed in CeFi platforms. As a crypto-native stablecoin, USDX offers a scalable, censorship-resistant, and highly stable solution for users looking to navigate the world of decentralized finance with confidence.

USDX Stablecoin

USDX Stablecoin is trending as community discussion focuses on its recent crash following the Balancer hack chaos, highlighting the fragility of DeFi stablecoins amidst ongoing efforts by major financial institutions to integrate crypto into traditional systems.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is experiencing a surge in attention driven by widespread community discussion and bullish sentiment regarding a "COEP Dogecoin merger" with 9,000 miners. The excitement is further amplified by general market optimism for meme coins and technical analysis pointing to bullish signals.

C.H. Robinson Worldwide, Inc. engages in the provision of freight transportation services and logistics solutions. It operates through the following segments: North American Surface Transportation (NAST), Global Forwarding, and All Other and Corporate. The NAST segment provides freight transportation services across North America through a network of offices in the United States, Canada, and Mexico. The Global Forwarding segment focuses on the global logistics services through an international network of offices in North America, Europe, Asia, Australia, New Zealand, and South America. The All Other and Corporate segment includes Robinson Fresh and Managed Services segments, as well as other surface transportation outside of North America and other miscellaneous revenues and unallocated corporate expenses. The company was founded by Charles Henry Robinson in 1905 and is headquartered in Eden Prairie, MN.

C.H. Robinson Worldwide, Inc.

C.H. Robinson Worldwide is drawing significant attention after a sector-wide sell-off driven by fears of AI disruption from a tiny challenger, sparking community debate over whether the reaction is overdone, especially given CHRW's existing AI leadership and recent insider purchases.

VeChain, founded in 2015, is a sustainability-focused blockchain driving mass adoption of Web3. Its energy-efficient VeChainThor chain delivers fast, low-cost transactions, making blockchain accessible to millions worldwide. With partnerships including UFC, BCG, and Walmart, and over 2 million active users on VeBetter-powered apps, VeChain is proving real-world impact at scale.  In 2024, the VeChain Renaissance upgrade was launched, introducing Ethereum compatibility, dPoS consensus, and dynamic gas fees. It cut VTHO inflation and introduced StarGate NFT staking, where users lock VET to mint transferable NFTs that earn VTHO, can be delegated to validators, and serve as governance instruments. The upgrade also added new eco node tiers, lowering entry barriers while keeping rewards across higher staking levels.  By combining adoption, upgraded tokenomics, and inclusive staking, VeChain is positioning itself as a leading blockchain where usage, growth, and rewards fuel long-term value creation.

Vechain

VeChain (VET) is trending with community frustration peaking over its prolonged underperformance and recent executive departures, as discussions highlight skepticism about its "real utility" while some investors continue to accumulate in anticipation of a broader altcoin market rally.

Caledonia Mining Corp. Plc engages in the exploration, development, and production of gold and other precious metals from its mineral properties. Its projects include Blanket Gold Mine and Maligreen. The company was founded on February 5, 1992 and is headquartered in St. Helier, the United Kingdom.

Caledonia Mining Corporation Plc

Caledonia Mining Corporation (CMCL) is actively discussed after a recent convertible note offering for its Bilboes Gold Project led to a significant share price pullback and concerns over dilution. While many investors express frustration that the stock has not mirrored gold's substantial rally, optimism remains high for CMCL's future given soaring gold prices and the project's potential to quadruple production.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola is trending as investors digest its Q4 earnings, which showed an EPS beat but revenue miss and cautious 2026 guidance, alongside a recent CEO transition. This sparks community debate over the stock's valuation and the sustainability of its recent 52-week highs amidst a rotation into defensive consumer staples.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Wolfpack also said that it believes the loss of funding for the contracts spurred the exit of the CEO Peter Chapman and insider trading.</li><li>The report further alleged that IONQ backfilled the lost Pentagon dollars by acquiring non-quantum computing businesses such as Capella, Vector Atomics and ID Quantique.&nbsp;</li><li>In March 2025, Kerrisdale Capital also issued a short report on the manufacturer of high-performance quantum computers.</li></ul>&nbsp;Shares of IONQ Inc (IONQ) slumped 12% on Wednesday at the time of writing after Wolfpack Research divulged a short position in the company.Wolfpack said that the quantum computing hardware and software company lost funding for Pentagon contracts that had comprised up to 86% of revenues from 2022-2024, leaving a $54.6 million black hole in their bookings in 2025.Wolfpack also said that it believes the loss of funding for the contracts spurred the exit of the CEO Peter Chapman and insider trading. As per the firm, insiders dumped about $396.6 million in stock.<h2 class="st-heading-2">Other Allegations</h2>The firm alleged that Pentagon was directed to enter the contracts with IONQ via secretive “backdoor earmarks” by politicians friendly to the company.The<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wolfpackresearch.com/items/ionq-has-lost-funding-for-vital-pentagon-contracts-that-had-represented-up-to-86%25-of-revenues-"> report </a>further alleged that IONQ backfilled the lost Pentagon dollars by acquiring non-quantum computing businesses such as Capella, Vector Atomics and ID Quantique.The form also criticized the company’s announced acquisition of Skywater Technology. “Is buying low-margin, highly cyclical businesses like $SKYT really the best use of the billions that IONQ has raised through dilution?,” the firm wrote.<h2 class="st-heading-2">Other Short Seller Reports</h2>Wolfpack is not the first to reveal a short position in IONQ. In March 2025, Kerrisdale Capital issued a short report on the manufacturer of high-performance quantum computers.Kerrisdale then said that IONQ is far from the cusp of a “new era of commercial success” due to its limited error-prone systems. The firm also expressed skepticism regarding the company's exponential growth claims and called out the management’s lack of transparency.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment toward IONQ stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.A Stocktwits user dismissed the short seller report, instead urging shareholders to hold for a few years.<stembedurl>https://www.stocktwits.com/byethedyp/message/643980985</stembedurl>Another deems the report as confirmation of a “scam.”<stembedurl>https://www.stocktwits.com/Big_Baggies/message/643986121</stembedurl><a href="https://stocktwits.com/symbol/IONQ">IONQ stock</a> has lost 19% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/oncy-stock-rallies-on-second-fast-track-designation-for-experimental-cancer-drug/cZbj4W6R4N5">ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, a person holds a smartphone displaying the logo of IONQ Inc.

IONQ Stock Tumbles 12% As Wolfpack Reveals Short Position

Wolfpack said that the quantum computing hardware and software company lost funding for Pentagon contracts that had comprised up to 86% of revenues from 2022-2024, leaving a $54.6 million black hole in their bookings in 2025. 

Equity

<ul class="summary-bullets"><li>In Kentucky, TeraWulf has acquired a former industrial site in Hawesville, which has approximately 480 MW of existing power availability.</li><li>In Maryland, where TeraWulf is headquartered, the company has acquired the Morgantown Generating Station.</li><li>This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually.</li></ul>Shares of TeraWulf (<a href="https://stocktwits.com/symbol/WULF">WULF</a>) surged more than 10% during extended hours of trading on Monday after the company announced that it is expanding its digital and power infrastructure portfolio.&nbsp;The company said it is expanding its portfolio through the acquisition of two strategically located brownfield infrastructure sites in Hawesville, Kentucky and Charles County, Maryland.<h2 class="st-heading-2">Details</h2>TeraWulf said these acquisitions added about 1.5 gigawatts (GW) of capacity to its portfolio and advanced the company’s strategy of developing energy-advantaged locations with near-term power availability, long-term scalability, and the ability to support customer demand and broader grid needs.In Kentucky, TeraWulf has acquired a former industrial site in Hawesville. The site includes more than 250 buildable acres for compute capacity and offers immediate access to robust power infrastructure, the statement said.&nbsp;The Hawesville site has approximately 480 megawatts (MW) of existing power availability, with the potential to further expand over time. Development is expected to occur in phases, allowing TeraWulf to scale efficiently alongside customer demand.In Maryland, where TeraWulf is headquartered, it has acquired the Morgantown Generating Station. The acquisition establishes TeraWulf’s presence in the Pennsylvania-New Jersey-Maryland (PJM) market and reinforces the company’s strategy of reinvesting in existing energy assets to support grid reliability and long-term economic activity.<h2 class="st-heading-2">Portfolio Expansion</h2>With the addition of these sites, TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites, including 642.5 MW of contracted capacity and 2.2 GW of owned pipeline capacity.This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually, aligned with customer demand, power availability, and regional grid conditions.“These acquisitions reflect our strategy of reinvesting in existing energy infrastructure to support grid reliability, long-term economic activity, and responsible growth,” said Paul Prager, Chairman and Chief Executive Officer of TeraWulf.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around WULF trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;One bullish user said that “2 additional site announcement today DOUBLES the AI/HPC capacity”.&nbsp;<stembedurl>https://stocktwits.com/AllMarkets/message/643740254</stembedurl>Shares in the company have jumped more than 200% over the past 12 months.&nbsp;&nbsp;

 In this photo illustration, the TeraWulf (Tera Wulf) logo is seen displayed on a smartphone screen.

Why Is TeraWulf Stock Rallying More Than 10% After Hours?

With the addition of these sites, TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites.

<ul class="summary-bullets"><li>CEO Catherine Owen Adams said that the negative trend vote is “disappointing” and “not what we hoped for.”</li><li>The committee will formally adopt its opinion in February and the company will request a re-examination, Acadia said.&nbsp;</li><li>Trofinetide is approved by the U.S. Food and Drug Administration to treat Rett syndrome.</li></ul>Shares of Acadia Pharmaceuticals Inc. (ACAD) fell over 8% after-hours on Monday after the company said that it was informed of a negative trend vote from a European Medicines Agency committee regarding its application for Trofinetide for the treatment of Rett syndrome.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260202406586/en/Acadia-Pharmaceuticals-Provides-Update-on-Regulatory-Submission-for-Trofinetide-for-the-Treatment-of-Rett-Syndrome-in-the-European-Union">said</a> that the Committee for Medicinal Products for Human Use informed it of a negative trend around its application after an oral explanation recently.The committee will formally adopt its opinion in February and the company will request a re-examination, the company said.<h2 class="st-heading-2">CEO Weighs In</h2>CEO Catherine Owen Adams said that the negative trend vote is “disappointing” and “not what we hoped for.”“...we believe the strong data that supported the approval of trofinetide for the treatment of Rett syndrome in the United States, Canada, and Israel speak to the meaningful benefits that trofinetide can deliver,” she said.<h2 class="st-heading-2">Timeline And Steps Ahead</h2>As per legislation in the EU, the company can request a re-examination of CHMP’s opinion within 15 days of receiving its formal opinion. The company will then have 60 days to submit reasons for the re-examination request which will then be reviewed by the committee.Trofinetide is approved by the U.S. Food and Drug Administration to treat Rett syndrome in adults and children. &nbsp;Rett syndrome is a rare genetic neurological and developmental disorder that affects the way the brain develops. This disorder causes a progressive loss of motor skills and language and primarily affects females.This marks the latest hardship for Acadia whose late-stage intranasal Carbetocin trial in Prader-Willi syndrome (PWS) patients failed to achieve a statistically significant improvement in hyperphagia in September.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ACAD stock stayed within the ‘neutral’ territory while message volume rose from ‘normal’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/ACAD">ACAD stock</a> has gained 41% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-spacex-acquires-grok-parent-xai/cZbgCs6R4ky">Elon Musk’s SpaceX Acquires Grok Parent xAI</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Acadia Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did ACAD Stock Slump 8% After Hours Today?

Acadia Pharmaceuticals said that the Committee for Medicinal Products for Human Use informed it of a negative trend around its application after an oral explanation recently.

<ul class="summary-bullets"><li>Last month, MarineMax said that its same store sales in the first quarter of fiscal year 2026 rose over 10% despite a challenging retail environment.</li><li>In addition to Donerail, other players have also expressed interest in acquiring MarineMax’s marina business, the report noted.</li><li>Donerail met with MarineMax’s management several times in recent months to express its concerns pertaining to capital allocations, as per Reuters.</li></ul>Shares of MarineMax (HZO) closed nearly 11% higher on Monday on the heels of a report that Donerail Group has offered to buy the company in a deal valued at just over $1 billion.Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/sustainability/sustainable-finance-reporting/donerail-offers-buy-superyacht-service-company-marinemax-all-cash-deal-valued-2026-02-02/">reported</a> on Monday, citing people familiar with the matter, that Donerail has offered $35 per share in cash for MarineMax. This represents a premium of over 29% from the stock’s closing price on Friday.Shares of MarineMax’s rival OneWater Marine Inc (ONEW) also closed up 2% after the news.<h2 class="st-heading-2">Acquisition Offer</h2>MarineMax is a recreational boat and yacht retailer, marina operator and superyacht services company. Last month, the company said that its same store sales in the first quarter of fiscal year 2026 rose over 10% despite a challenging retail environment.As per Reuters, MarineMax hired Wells Fargo after receiving the offer from Donerail. The report also noted that Donerail met with management several times in recent months to express its concerns pertaining to capital allocations. While MarineMax made some changes at the company and replaced directors, they were not satisfactory to Donerail, the report added. &nbsp;In addition to Donerail, other players have also expressed interest in acquiring MarineMax’s marina business, the report noted.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around HZO remained within the ‘neutral’ territory over the past 24 hours while message volume stayed at ‘high’ levels.A Stocktwits user opined that Donerail’s offer is undervaluing the company and pegged the company’s worth at “$55 minimum.”<stembedurl>https://www.stocktwits.com/Wake44/message/643734683</stembedurl><a href="https://stocktwits.com/symbol/HZO">HZO stock</a> has gained about 2% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/acad-stock-slumps-after-hours-on-hurdles-to-eu-approval-for-genetic-disorder-drug/cZbgCddR4kx">Why Did ACAD Stock Slump 8% After Hours Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

MarineMax Shares Rally On Reported Buyout Offer: Here Are The Details

Reuters reported on Monday, citing people familiar with the matter, that Donerail has offered $35 per share in cash for MarineMax.

<ul class="summary-bullets"><li>The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab without Anktiva.</li><li>Durable complete responses were observed in heavily pretreated patients with iNHL in the study, including Waldenström’s Macroglobulinemia, the company said.</li><li>Last month, Immunitybio said that it recently met with the U.S. FDA to discuss its application for Anktiva plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.</li></ul>Immunitybio Inc. (IBRX) said on Monday that it has launched a mid-stage clinical study in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) with no need for chemotherapy.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell">said</a> that outpatient study will evaluate ImmunityBio’s novel, off-the-shelf cell therapy CD19 CAR-NK in combination with its other drug Anktiva and Rituximab, and will not require any lymphodepleting chemotherapy unlike conventional CAR-T cell therapies.<h2 class="st-heading-2">Why The Trial?</h2>The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab without Anktiva. Durable complete responses were observed in heavily pretreated patients with iNHL in the study, including Waldenström’s Macroglobulinemia, the company said.The new mid-stage study is designed to evaluate whether further stimulation of innate and adaptive immune responses may enhance the depth and durability of anti-tumor activity, Immunitybio said, while adding that the company is hopeful for Anktiva potentially augmenting the actions of the cell therapy and Rituximab.The study will enroll patients with indolent NHL, including Waldenström’s Macroglobulinemia, who are relapsed or are refractory after at least two prior lines of therapy. Treatment will be provided without chemotherapy.<h2 class="st-heading-2">Anktiva Troubles</h2>Last month, Immunitybio said that it recently met with the U.S. Food and Drug Administration to discuss its application for Anktiva plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.The company had submitted the application in 2025 but was rejected and is now looking to resubmit it with more information. The company then said that it would submit the additional information within 30 days, and that the added information does not need a new trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IBRX shares remained within the ‘bullish’ territory, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained about 90% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-seemingly-confirms-xai-spacex-merger-talks/cZbgtmrR4kZ">Elon Musk Seemingly Confirms xAI-SpaceX Merger Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs

The company said that outpatient study will evaluate ImmunityBio’s novel, off-the-shelf cell therapy CD19 CAR-NK in combination with its other drug Anktiva and Rituximab.

<ul class="summary-bullets"><li>The committee had issued a negative opinion on approving the new dosing regimen in October after it deemed the submitted data as insufficient to conclude on efficacy.</li><li>Protalix said that it will be eligible to receive a regulatory milestone payment of $25 million from Chiesi Global Rare Diseases if the new dosing regimen is approved by the EMA.</li></ul>Shares of Protalix BioTherapeutics, Inc. (PLX) closed 13% higher on Friday after it announced that a European Medicines Agency committee has recommended approval of a new dosing regimen for pegunigalsidase alfa, marketed as Elfabrio, in Fabry disease.The Committee for Medicinal Products for Human Use <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.protalix.com/news-releases/news-release-details/chiesi-global-rare-diseases-and-protalix-biotherapeutics-4">recommended</a> approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients. Currently approved dosing regimen requires patients to visit infusion centers every two weeks for treatment while the proposed new regimen would allow it to be stretched to every four weeks.<h2 class="st-heading-2">Turnaround</h2>The positive opinion follows CHMP’s re-examination of the company’s application for the additional dosing regimen. The committee had issued a negative opinion on approving the new dosing regimen in October after it deemed the submitted data as insufficient to conclude on efficacy.Protalix said that it will be eligible to receive a regulatory milestone payment of $25 million from Chiesi Global Rare Diseases if the new dosing regimen is approved by the EMA. The agency is expected to announce a decision by March 2026.Fabry disease is a rare, inherited X-linked lysosomal storage disorder caused by a deficiency in the alpha-galactosidase A enzyme, leading to harmful accumulation of fats in cells. Symptoms include severe neuropathic pain in hands/feet, skin lesions, decreased sweating, and organ damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PLX stock improved from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user appreciated that the company was persistent in getting a positive opinion. However, the stock should have rallied more on the news, they said.“But the $25 million is great news and hopefully should lessen the risk of capital raise for their gout trials. Finally, one decent obstacle out of the way,” they wrote.<stembedurl>https://www.stocktwits.com/BryGuy29/message/643515194</stembedurl><a href="https://stocktwits.com/symbol/PLX">PLX stock</a> has dropped about 2% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/peloton-reportedly-lays-off-11-percent-workforce/cmySvT7R4Sv">Peloton Reportedly Lays Off 11% Workforce Including Engineers In Cost-Cutting Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy

The Committee for Medicinal Products for Human Use recommended approval of the 2mg/kg every-4-weeks dosing regimen in Fabry disease adult patients.

<ul class="summary-bullets"><li>The company is slated to announce its second-quarter earnings next week before the U.S. stock market opens on Thursday.&nbsp;</li><li>The company had said in November that it expects Q2 revenue in the range of $665 million to $685 million and adjusted core profit in the range of $55 million to $75 million.</li><li>The company recently launched AI-powered bikes and treadmills.</li></ul> Peloton Interactive Inc. (PTON) has reportedly slashed 11% of its workforce in a bid to cut costs at the company.Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-01-30/peloton-cuts-11-of-staff-including-from-engineering-teams">reported </a>on Friday, citing a person familiar with the matter, that CEO Peter Stern informed staff of the move. The workforce reduction mostly impacts engineers working on technology and enterprise-related efforts, the report said.PTON shares closed down 2% in the regular trading session and edged up marginally after hours.<h2 class="st-heading-2">Upcoming Q2 Earnings</h2>The company is slated to announce its second-quarter (Q2) earnings next week before the U.S. stock market opens on Thursday, Feb. 5. Analysts, on average, expect the exercise equipment maker to report quarterly revenue of $675.13 million, compared to the $673.90 million reported in the corresponding quarter of fiscal year 2025, and loss per share of $0.05.The company had said in November that it expects Q2 revenue in the range of $665 million to $685 million and adjusted core profit in the range of $55 million to $75 million.For fiscal year 2026, the company expects year-over-year decline in revenue to a range of $2.4 billion to $2.5 billion and an increased adjusted core profit of $425 million to $475 million.The company recently launched AI-powered bikes and treadmills featuring Peloton IQ, which includes form feedback, movement tracking, and voice control, intended to enhance user experience. However, Bloomberg reported in November that it had seen sluggish sales till then.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PTON stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.A Stocktwits user wrote, “Peloton is signaling “survive first, grow later.”<stembedurl>https://www.stocktwits.com/PickAlpha/message/643513062</stembedurl><a href="https://stocktwits.com/symbol/PTON">PTON stock</a> has dropped 31% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/first-solar-shares-rebound-as-wall-street-dismisses-tesla-competition-concerns/cmySM1MR4Su">First Solar Shares Rebound As Wall Street Dismisses Tesla Competition Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Sign at the entrance to the Peloton offices in Midtown Manhattan. (Photo by Erik McGregor/LightRocket via Getty Images)

Peloton Reportedly Lays Off 11% Workforce Including Engineers In Cost-Cutting Efforts

The workforce reduction mostly impacts engineers working on technology and enterprise-related efforts, the report said.

<ul class="summary-bullets"><li>H.C. Wainwright said KRRO-121 adds a second, "independently risk-mitigated asset as a call option."</li><li>Piper Sandler said it left the company’s analyst day on Tuesday with "strong conviction" for KRRO-121's probability of success.</li><li>Oppenheimer upgraded Korro Bio to ‘Outperform’ from ‘Perform’ with a $22 price target.</li></ul>Shares of Korro Bio Inc. (KRRO) jumped 13% on Thursday after multiple analysts upgraded the stock on optimism about the company’s new development candidate KRRO-121.Korro is now looking to study the drug in the treatment of hyperammonemia. The company said on Tuesday that it intends to file an application in the second half of 2026 to begin its first in-human trial for the candidate.<h2 class="st-heading-2">Analysts Chime In</h2>H.C. Wainwright upgraded Korro Bio to ‘Buy’ from ‘Neutral’ with a $20 price target, according to TheFly. The firm said KRRO-121 adds a second, "independently risk-mitigated asset as a call option."Korro shares are trading near a zero enterprise value, the analyst told investors in a research note. H.C. Wainwright believes KRRO-121 is not a read-through from KRRO-110,"so this is a truly independent shot on goal."Piper Sandler analyst Yasmeen Rahimi on Wednesday also upgraded Korro Bio to ‘Overweight’ from ‘Neutral’ with a price target of $30, up from $11. Piper said it left the company’s analyst day on Tuesday with "strong conviction" for KRRO-121's probability of success, it said.The firm is bullish ahead of KRRO-121's new drug filing in the second half of 2026, saying there is a "clear precedence for a regulatory path."Oppenheimer also upgraded Korro Bio to ‘Outperform’ from ‘Perform’ with a $22 price target. The firm believes the company's probability of success is now reset and that KRRO-121 offers a fresh, interesting story wherein RNA editing can thrive. The firm sees potential for significant upside.<h2 class="st-heading-2">Pivot From KRRO-110</h2>In November, Korro said that in its <a href="https://stocktwits.com/news-articles/markets/equity/korro-bio-stock-crashes-over-75-after-hours-on-drug-failure-downgrades-and-layoffs/cLPBNsbREdA">trial</a> evaluating KRRO-110 in the genetic disorder called Alpha-1 Antitrypsin Deficiency (AATD), it achieved functional protein production with a single administration, but it did not achieve the protein levels projected based on preclinical data.The lower-than-expected results prompted a 34% reduction in working and the company subsequently opted KRRO-121 as its next development candidate, for the potential treatment of patients with hyperammonemia.Hyperammonemia is a critical metabolic condition defined by abnormally elevated blood ammonia levels, commonly resulting from liver failure (cirrhosis) or inherited urea cycle disorders. It causes acute, severe neurological impairment—including encephalopathy, seizures, coma, and cerebral edema—and requires immediate medical intervention to prevent fatal brain damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around KRRO stock rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that a strong momentum setup is shaping up, adding that buyers are defending these levels and pushing higher.<stembedurl>https://www.stocktwits.com/topstockalerts/message/643304339</stembedurl><a href="https://stocktwits.com/symbol/KRRO">KRRO shares</a> have dropped 60% in the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/trump-administration-reportedly-ready-to-lay-out-crypto-law/cmyikhjR41I">Trump Administration Reportedly Ready To Lay Out Crypto Rules</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

KRRO Shares Jump 13% On Analyst Upgrades — What’s Driving The Optimism?

The company said on Tuesday that it intends to file an application in the second half of 2026 to begin its first in-human trial for its new development candidate KRRO-121. 

<ul class="summary-bullets"><li>Leerink said the premarket selloff in shares underscores the degree of surprise on the news, feeding into the "FDA unpredictability" element of the bear thesis across gene therapy.</li><li>It is not known if the RGX-111 integration was causative of the neoplasm and the patient was asymptomatic and doing well on the therapy, Clear Street analyst Bill Maughan said.&nbsp;</li><li>Stifel, however, expects a delay in FDA approval for RGX-121 in the treatment of Hunter Syndrome.</li></ul>Shares of REGENXBIO Inc.’s (RGNX) pared some losses on Wednesday after Wall Street dismissed an earlier selloff as an overreaction.The company <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rgnx-stock-falling-today/cmyg4cKR404">announced</a> earlier on Wednesday that the U.S. Food and Drug Administration placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of Hurler syndrome. The hold followed a case of tumor in a child participant treated in a study with RGX-111. The news sent shares of the company tumbling about 30% premarket. The causality between the tumor and the experimental therapy has not been established and investigation is ongoing, the company noted.The agency also placed a hold on RGX-121, being studied in the treatment of Hunter Syndrome, citing similarities between the two products, study populations and shared risks.<h2 class="st-heading-2">Wall Street Dismisses Selloff</h2>However, Leerink said the premarket selloff in shares underscores the degree of surprise on the news, feeding into the "FDA unpredictability" element of the bear thesis across gene therapy. However, the firm views this pullback as "an overreaction" based on the modest financial contribution of Hunter/Hurler to the fundamental value of shares and views this as a buying opportunity. Leerink has an ‘Outperform’ rating on Regenxbio shares.Clear Street analyst Bill Maughan, meanwhile, reiterated a ‘Buy’ rating on Regenxbio with a $50 price target. The firm believes the clinical hold has a limited impact on the stock's thesis. It is not known if the RGX-111 integration was causative of the neoplasm and the patient was asymptomatic and doing well on the therapy, the analyst told investors in a research note.Stifel, too, reiterated a ‘Buy’ rating on Regenxbio with a price target of $45. Neoplasm warnings are on other gene therapies, and the risk-benefit remains favorable, the analyst said, while adding that it still expects a delay in FDA approval for RGX-121. The FDA is expected to rule on potential approval for the therapy by Feb. 8.RGNX shares traded 17% lower at the time of writing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RGNX stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user dismissed hopes for a FDA approval of RGX-121 by Feb 8. “11 days is not enough time to clear a safety hold of this magnitude,” they wrote.<stembedurl>https://www.stocktwits.com/Teillbou/message/643165513</stembedurl>“I think the news is worse than the price action,” another user wrote.<stembedurl>https://www.stocktwits.com/kenny91655/message/643185332</stembedurl><a href="https://stocktwits.com/symbol/RGNX">RGNX shares</a> have gained 46% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/halo-stock-edges-up-on-upbeat-multi-year-revenue-guidance-surf-bio-acquisition/cmygWBXR408">HALO Stock Edges Up 3% On Upbeat Multi-Year Revenue Guidance, Surf Bio Acquisition</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

RGNX Shares Pare Losses As Wall Street Dismisses Gene Therapy Clinical Hold Spurred Selloff As An Overreaction

The company announced earlier on Wednesday that the U.S. Food and Drug Administration placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of Hurler syndrome.

<ul class="summary-bullets"><li>Barclays said Bloom is positioned to benefit from rising onsite-power demand and strong hyperscaler momentum.</li><li>Baird on Tuesday said it has updated its model after it previewed Q4 results where it expects guidance to be conservative but consensus achievable.&nbsp;</li><li>Bloom Energy is expected to report its fourth quarter results next week.&nbsp;</li></ul>Bloom Energy shares rallied on Wednesday after several brokerages initiated their coverage on the stock.&nbsp;The company has seen several price target hikes recently as analysts remain confident on the company's outlook as well as upcoming fourth quarter results, due next week.<h2 class="st-heading-2">Coverage Initiated</h2>Barclays on Wednesday initiated coverage of Bloom Energy with an ‘Equal Weight’ rating and $153 price target.&nbsp;The company's solid-oxide fuel cells have emerged as a "compelling alternative" for on-site generation due to its declining costs, quick time to market, and ability to provide baseload power, the analyst told investors in a research note.&nbsp;The firm said Bloom is positioned to benefit from rising onsite-power demand and strong hyperscaler momentum. However, the stock's valuation already prices in "meaningful scale-up toward," contended Barclays.China Renaissance also initiated coverage of Bloom Energy with a ‘Buy’ rating and $207 price target.<h2 class="st-heading-2">Upbeat Analysts</h2>Baird on Tuesday raised the firm's price target on Bloom Energy to $172 from $157 and kept an ‘Outperform’ rating on the shares. The firm updated its model after it previewed Q4 results where they expect guidance to be conservative but consensus achievable.&nbsp;Clear Street analyst Tim Moore also raised the firm's price target on Bloom Energy to $80 from $68 and kept a ‘Hold’ rating on the shares ahead of the company's scheduled December quarter report on February 5.Ahead of earnings, Clear Street has increased its assumption for a larger sales contribution from the American Electric Power (AEP) order in Wyoming and now believes Bloom could achieve about 500 MW of fuel cells for that site. As such, the firm increased its 2026 sales forecast by 2% and its 2027 sales forecast by 4%.<h2 class="st-heading-2">Q4 Earnings Ahead</h2>Bloom Energy is expected to report fourth quarter revenue of $647.6 million according to Wall Street estimates, as per data from Fiscal.ai.The company is expected to post a profit of $0.31 per share in the fourth quarter.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BE trended in ‘neutral’ territory amid ‘high’ message volume.&nbsp;Shares in the company have jumped 618% over the past 12 months.&nbsp; &nbsp;

In this photo illustration, the Bloom Energy (Be) logo is seen displayed on a smartphone screen. 

Bloom Energy Shares Surge – Why Are Analysts Initiating Coverage On The Stock?

Brokerages like Barclays and China Renaissance initiated coverage on Bloom Energy. 

iShares Trust - iShares Russell 2000 BuyWrite ETF

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

IWMW
iShares Russell 2000 BuyWrite ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWMW News

IWMWiShares Russell 2000 BuyWrite ETF